Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Revolution Medicines, Inc. Common Stock

Revolution Medicines focuses on developing targeted therapies for cancer treatment. The company is self-described as being 'on target' to outsmart cancer.

COM:REVMED

Revolution Medicines

Last Close

56.78

22/11 21:00

Market Cap

9.55B

Beta: -

Volume Today

1.17M

Avg: -

People Not Available